The Science of Urolithin A: Clinical Studies & Evidence
Most supplement ingredients rest on test-tube studies and marketing. Urolithin A is a rare exception: nearly a decade of research culminating in multiple randomized, placebo-controlled human clinical trials published in leading peer-reviewed journals. This is a thorough, honest walkthrough of that evidence — the mechanism, the trials, the safety data, the emerging frontiers, and the limits.
The evidence hierarchy: why this matters
Not all “studies” are equal. A compound that looks promising in cells often does nothing in animals; something that works in animals often fails in people. The gold standard is the randomized, double-blind, placebo-controlled human trial — where neither participants nor researchers know who received the compound. Urolithin A has cleared that bar more than once, which is uncommon in the supplement world. Below, the research is presented roughly in that order: mechanism, then the human trials, then what's still emerging.
The mechanism: mitophagy
Urolithin A's story begins with mitophagy — the process by which cells identify and clear out damaged mitochondria (their energy engines) so healthier ones can take over. Mitophagy declines with age, allowing worn-out mitochondria to accumulate and cellular energy to suffer.
In landmark preclinical work (Ryu et al., Nature Medicine, 2016), researchers screening gut-derived metabolites identified urolithin A as a compound that induces mitophagy. In that work it extended lifespan in C. elegans and improved muscle function in rodents, including aged mice. That discovery is the foundation every subsequent human trial was built on. For a plain-English explainer, see what is mitophagy.
The human clinical trials
Safety and target engagement
The first randomized, double-blind, placebo-controlled human trial tested single and repeated (28-day) doses of urolithin A, up to 1,000 mg, in sedentary older adults.
- Safety: urolithin A was safe and well tolerated at all doses tested, with a pharmacokinetic profile showing it reaches the bloodstream.
- Biology: it induced favorable changes in plasma acylcarnitines and a skeletal-muscle gene-expression signature associated with improved mitochondrial function — evidence it actually engages the biology it targets.
- Why it matters: this established both safety and “target engagement,” the prerequisites for the efficacy trials that followed.
Muscle endurance and biomarkers
A four-month randomized, placebo-controlled trial in older adults (roughly ages 65-90) compared 500 mg and 1,000 mg per day against placebo.
- Muscle endurance: the trial reported improvements in muscle endurance (more muscle contractions before fatigue) versus placebo.
- Biomarkers: favorable changes in several plasma markers related to mitochondrial function and inflammation.
- Safety: well tolerated over four months, consistent with the earlier safety data.
Muscle strength and exercise performance
A randomized, placebo-controlled trial in middle-aged adults used 500 mg and 1,000 mg per day over four months.
- Strength: improvements in muscle strength versus placebo.
- Performance: improvements in measures of exercise performance and aerobic endurance.
- Mitochondrial markers: favorable changes in biomarkers of mitochondrial health.
- Dosing insight: because both 500 mg and 1,000 mg showed effects, this trial is a key reason both are considered clinically studied doses.
Extending into active populations
More recent randomized, placebo-controlled work examined urolithin A in resistance-trained adults over eight weeks, looking at muscle endurance and strength alongside markers of inflammation, oxidative stress, and protein metabolism — broadening the evidence beyond older and sedentary groups.
Safety and tolerability
Across the human trials — at doses up to 1,000 mg per day for as long as four months — urolithin A has been consistently reported as safe and well tolerated, with side effects uncommon and generally mild. This aligns with the fact that urolithin A is a natural product of human digestion, not a foreign chemical. Standard caveats still apply: if you are pregnant, nursing, taking medication, or managing a health condition, check with your doctor first. See our side effects and safety guide.
Emerging and preclinical research
Beyond muscle, urolithin A is being explored in several areas — but it's important to label these honestly as early or preclinical, not established human benefits:
Joints and cartilage
Preclinical (animal) research has explored urolithin A's effects on mitochondrial health in cartilage and joint tissue. Promising in models, but not established in human trials.
Immune cell function
Preclinical work has investigated urolithin A's influence on immune-cell mitophagy and function. Intriguing, early, and not yet human-proven.
Skin and cellular aging
Early research has looked at urolithin A and skin at the cellular level. This is emerging and less established than the muscle evidence — see urolithin A for skin.
What the evidence does NOT show
Being evidence-led means being clear about limits:
• Urolithin A is a structure/function supplement — it supports muscle and mitochondrial health. It is not shown to treat, cure, or prevent any disease.
• There is no human data showing lifespan extension or “reversing aging.”
• Several effects are measured at the biomarker level or are modest in size; this is normal for a supportive ingredient, not a drug.
• Much of the pivotal human research has involved industry funding and collaboration (notably the company behind the branded Mitopure form). The trials are peer-reviewed and independently published, but transparency about funding matters, and larger independent, long-term trials are still valuable.
The clinically studied dose
Across the human trials, the doses were 500 mg to 1,000 mg per day, taken consistently over weeks to months. The 1,000 mg dose was associated with the strongest mitochondrial gene-expression response, which is why it's a sensible target. See our dosage guide. SOMA HEALTH Urolithin A Gummies deliver the full 1,000 mg per serving.
Frequently asked questions
Is urolithin A backed by clinical research?
Yes — multiple randomized, double-blind, placebo-controlled human trials, published in Nature Metabolism, JAMA Network Open, and Cell Reports Medicine, plus foundational work in Nature Medicine.
What did the trials actually find?
That urolithin A is safe and well tolerated up to 1,000 mg/day, and can support muscle endurance, muscle strength, exercise performance, and biomarkers of mitochondrial health.
Who funded the studies?
Much of the pivotal research involved the company behind the branded Mitopure form of urolithin A. The studies are peer-reviewed and independently published, and we think transparency about that is important.
Does urolithin A extend human lifespan?
No human trial shows lifespan extension. Lifespan effects have only been seen in simple organisms; human evidence is about safety and muscle/mitochondrial support.
Is 1,000 mg a safe dose?
1,000 mg per day was used in the human trials and was well tolerated. There's no established benefit to exceeding the studied range.
References
- Andreux P.A., et al. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 1, 595-603. nature.com
- Liu S., D'Amico D., et al. (2022). Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open, 5(1):e2144279. jamanetwork.com
- Singh A., et al. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine, 3(5):100633. PubMed
- Ryu D., et al. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine, 22, 879-888. nature.com
- D'Amico D., et al. (2022). Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis (preclinical). PMC
- Randomized controlled trial of urolithin A in resistance-trained athletes (2024). Journal of the International Society of Sports Nutrition. tandfonline.com
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This page summarizes published research for educational purposes and is not a substitute for advice from a qualified healthcare provider. Studies are linked to their original sources; readers are encouraged to review the primary literature.
A clinically studied 1,000 mg dose of Urolithin A in one simple daily gummy — to support mitophagy, muscle strength, and cellular energy.
Shop SOMA Urolithin A Gummies →